ProteinLogic has developed ImmiPrint®, a novel diagnostic technology platform, based on the detection of non-obvious diagnostic patterns in soluble immune proteins in the blood and other body fluids through machine learning. These patterns form unique signatures of disease presence, stage, and potential response to treatment.

The ImmiPrint® technology has now been validated clinically with the development of a signature in blood for the ruling out of Active Tuberculosis (TB), meeting the stringent criteria of the WHO for such a diagnostic test. Along with HIV/AIDS, TB is the most significant infectious disease worldwide. Early and accurate diagnosis of Active TB disease is essential for its control.

In addition to developing its TB diagnostic test, the Company expects to create considerable additional value through the validation of other ImmiPrint® signatures in its early stage development pipeline, with a focus on infectious, autoimmune and inflammatory diseases.